A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma

The present phase II study has demonstrated that augmenting neutrophil function by the addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin lymphoma while retaining the excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population for whom therapeutic options are limited owing to poor tolerance.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other c ohorts.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
ConclusionThere are a number of challenges associated with the use of copanlisib. Infusion-related hypertension and hyperglycemia occur frequently, although they are transient, reversible, and rarely of clinical significance; this report provides guidance as to their management.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conditions:   Relapse or Refractory Acute Myeloid Leukemia;   Relapse or Refractory Non-Hodgkin Lymphoma;   Relapse or Refractory Multiple Myeloma Intervention:   Drug: S65487 Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionThis review provides estimates for response and survival to aid in decision making when considering ASCT for patients with PCNSL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma, with an estimated incidence of>25,000 cases in 2016, representing roughly one-quarter of all newly diagnosed mature lymphoid neoplasms.1 High grade B cell lymphoma (HGBL) is a less frequently-occurring subtype of non-Hodgkin lymphoma, and was first identified in the 2016 revision of the World Health Organization classification of lymphoid neoplasms, replacing the former category of B cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
IntroductionChronic graft-versus-host disease (cGVHD) affects up to 50% of the long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT), and is the leading cause of mortality in patients who survive to two years post-transplant. Unlike acute GVHD (aGVHD), the primary pathology in cGVHD is fibrotic, affecting the skin, and lacrimal and salivary glands, and shares many features with the autoimmune conditions Sjogrens syndrome and systemic sclerosis. Certain gastrointestinal microbiota compositions have been associated with these autoimmune conditions, and we thus hypothesized that the configuration of ...
Source: Blood - Category: Hematology Authors: Tags: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Biomarkers and the Microbiome Source Type: research
Conclusion: While providing potential clinical benefit, CAR T cell therapy utilizes resources across the therapeutic spectrum, and increasing use of this therapeutic modality can create challenges in institutional resource capacity. Identifying these resources will allow for better care delivery and allocation of funds. Further refinement of CAR T cell products and improvements in CAR T cell-related toxicity management may permit safer delivery of this therapy and reduce costs per patient. Additional analysis of resource utilization among patients treated with commercial CAR T cell products, as well as comparison with alte...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Overuse, Costs, and Utilization of Health Services Source Type: research
Conclusions: This analysis represents the largest report of outcomes in patients who have received a CD34+ selected stem cell infusion without conditioning for GF. Negative donor/recipient CMV serostatus and sex matching predicted response. In responding patients, GF initially affecting
Source: Blood - Category: Hematology Authors: Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Comorbidity and Novel Strategies to Improve Graft Function Source Type: research
There is no standard therapy for patients with myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMA) and the median overall survival (OS) of HMA-refractory MDS patients with IPSS Intermediate-2/High-risk MDS is ~6 months. Here, we present data from a phase 2 clinical trial of selinexor, an oral, first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that inhibits XPO1, in patients with MDS refractory to HMAs. XPO1 is the major nuclear export protein responsible for shuttling many key cellular regulators out of the nucleus and is overexpressed in many cancers. Preclinical studies of seline...
Source: Blood - Category: Hematology Authors: Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Novel Therapeutics I Source Type: research
Background: Prior studies have demonstrated disparities in the utilization of stem cell transplant (SCT) based on age, race, and insurance type. Whether delays to SCT occur as a result of these disparities is not well established. We evaluated whether we observed similar trends in a large metropolitan SCT center with a large population of minority patients (pts).Methods: We identified pts at Karmanos Cancer Institute who had their initial SCT consultation from 2009 - 2016, and evaluated pts who received or did not receive SCT for the diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplast...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Costs and Disparities Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Rituxan | Study